Editas Medicine
David Scadden is a board member at Editas Medicine. David was previously a company president at Agios Pharmaceuticals, FogPharma, Magenta Therapeutics, and Fate Therapeutics Inc. David Scadden has also been a faculty member at Harvard Medical School and Harvard University, as well as a physician at Massachusetts General Hospital.
This person is not in the org chart
This person is not in any teams
Editas Medicine
5 followers
Editas Medicine is a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Their goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.